BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Uterine cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
51 results:

  • 1. Mismatch repair gene
    Zhou LZ; Xiao HQ; Chen J
    Front Immunol; 2024; 15():1302797. PubMed ID: 38390329
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Metastasis of endometrial adenocarcinoma masquerading as a primary rectal cancer: A rare case report with literature review.
    Li M; Zheng W
    Medicine (Baltimore); 2023 Nov; 102(46):e36170. PubMed ID: 37986305
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Applicability of the FDA-approved Immunohistochemical Panel for Identification of MMRd Phenotype in uterine Endometrioid Carcinoma.
    Adachi S; Kimata JI; Hanami K; Adachi K; Igarashi T; Liang SG; Ishida Y; Fujino T; Yamazaki K
    Appl Immunohistochem Mol Morphol; 2024 Jan; 32(1):24-31. PubMed ID: 37859432
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A retrospective study of consistency between immunohistochemistry and polymerase chain reaction of microsatellite instability in endometrial cancer.
    Wang C; Kuang W; Zeng J; Ren Y; Liu Q; Sun H; Feng M; Liang D
    PeerJ; 2023; 11():e15920. PubMed ID: 37663290
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The Evolving Spectrum of Endometrial Glandular Proliferations With Corded and Hyalinized Features.
    Pors J; Weiel JJ; Ryan E; Longacre TA
    Am J Surg Pathol; 2023 Sep; 47(9):1067-1076. PubMed ID: 37493099
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
    Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Ovarian Mesonephric-Like Adenocarcinoma With Recurrent Liver Metastases: A Case Report with Analysis of Therapeutic Molecular Targets.
    Sugitani A; Ogawa A; Yoshida H; Kobayashi-Kato M; Kikkawa N; Tanase Y; Uno M; Ishikawa M; Kato T
    Int J Surg Pathol; 2024 May; 32(3):578-585. PubMed ID: 37345348
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Germline drivers of gynecologic carcinosarcomas.
    Sia TY; Gordhandas SB; Birsoy O; Kemel Y; Maio A; Salo-Mullen E; Sheehan M; Hensley ML; Rubinstein M; Makker V; Grisham RN; O'Cearbhaill RE; Roche KL; Mueller JJ; Leitao MM; Sonoda Y; Chi DS; Abu-Rustum NR; Berger MF; Ellenson LH; Latham A; Stadler Z; Offit K; Aghajanian C; Weigelt B; Mandelker D; Liu YL
    Gynecol Oncol; 2023 Jul; 174():34-41. PubMed ID: 37149903
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pure and mixed clear cell carcinoma of the endometrium: A molecular and immunohistochemical analysis study.
    Reijnen C; Vrede SW; Eijkelenboom A; Draak R; Sweegers S; Snijders MPLM; van Gestel P; Pijnenborg JMA; Bulten J; Küsters-Vandevelde HVN
    Cancer Med; 2023 Jun; 12(11):12365-12376. PubMed ID: 37081760
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
    Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
    Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Endometrioid Endometrial Carcinoma With NKX3.1 Expression in a Transgender Man: A Case Report.
    Yoshida H; Uno M; Ogimoto K; Kobayashi-Kato M; Tanase Y; Ishikawa M; Kato T
    Int J Gynecol Pathol; 2023 May; 42(3):308-314. PubMed ID: 36811847
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comparison of Tissue Mismatch Repair Protein Deficiency between Early- and Advanced-Stage Endometrial cancer.
    Chaowiwatkun K; Trongwongsa T; Rodpenpear N; Nutthachote P
    Asian Pac J Cancer Prev; 2023 Jan; 24(1):345-351. PubMed ID: 36708586
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
    Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
    Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
    Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
    Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The statuses of HER2 expression and mismatch repair in endometrial clear cell carcinoma.
    Bayramoglu Z; Erozbek SY; Ozdemir IA; Ulker V; Muezzinoglu B
    Pathol Res Pract; 2023 Jan; 241():154258. PubMed ID: 36516643
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Elucidation of genomic origin of synchronous endometrial and ovarian cancer (SEO) by genomic and microsatellite analysis.
    Sakamoto I; Hirotsu Y; Amemiya K; Nozaki T; Mochizuki H; Omata M
    J Gynecol Oncol; 2023 Jan; 34(1):e6. PubMed ID: 36245225
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Morphologic and Molecular Heterogeneity of Cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
    Ordulu Z; Mino-Kenudson M; Young RH; Van de Vijver K; Zannoni GF; Félix A; Burandt E; Wong A; Nardi V; Oliva E
    Am J Surg Pathol; 2022 Dec; 46(12):1670-1681. PubMed ID: 36069807
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.
    Kim JH; Kwon BS; Kim H; Suh DH; Kim K; Kim YB; No JH
    Taiwan J Obstet Gynecol; 2022 May; 61(3):415-421. PubMed ID: 35595431
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Utility of germline multi-gene panel testing in patients with endometrial cancer.
    Karpel HC; Chern JY; Smith J M; Smith A J; Pothuri B
    Gynecol Oncol; 2022 Jun; 165(3):546-551. PubMed ID: 35483985
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The clinical features and management of Lynch syndrome-associated ovarian cancer.
    Ran X; Jing H; Li Z
    J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.